Xofigo, also known as radium-223 dichloride, is a radioactive therapeutic agent used to treat patients whose prostate cancer has not responded to treatments that lower testosterone levels and has spread to the bones but not to other organs. It works by mimicking calcium and binding to areas of increased bone turnover, delivering targeted radiation therapy to cancerous bone cells while minimizing damage to surrounding healthy tissue.